Clinical implications of epigenetics in Renal Cell Carcinoma
- 27 July 2022
- journal article
- Published by Peertechz Publications Private Limited in Archives of Renal Diseases and Management
- Vol. 7 (1), 008-013
- https://doi.org/10.17352/2455-5495.000040
Abstract
Renal Cell Carcinoma (RCC), is the 9th most common cancer in the United States. The major classifications of RCC include clear cell (ccRCC), papillary (pRCC) and chromophobe (chRCC). Treatment for the localized disease includes resection or ablation with curative intent, or surveillance if these procedures are not feasible. Unfortunately, about one-third of patients will present with metastatic disease at the time of diagnosis and there are currently no reliable biomarkers to guide clinical decision-making. There is growing evidence that epigenetics plays a role in kidney cancer tumorigenesis and aggressiveness and new strategies for biomarker development are emerging. For example, DNA methylation patterns may be useful in distinguishing different types of RCCs and for distinguishing malignant kidney neoplasms from benign tumors. Epigenetic changes in RCC have also been associated with poorer response to treatment and have the potential to be novel drug targets in the treatment of mRCC. Here we discuss the epigenetics of RCC and the corresponding clinical implications.Keywords
This publication has 44 references indexed in Scilit:
- Integrated molecular analysis of clear-cell renal cell carcinomaNature Genetics, 2013
- A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancerInvestigational New Drugs, 2012
- Epigenetics of kidney cancer and bladder cancerEpigenomics, 2011
- Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinomaOncogene, 2010
- Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinomaInternational Journal of Cancer, 2010
- Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinomaOncogene, 2010
- Epigenetics in cancerCarcinogenesis: Integrative Cancer Research, 2009
- Global Levels of Histone Modifications Predict Prognosis in Different CancersThe American Journal of Pathology, 2009
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal TumorsClinical Cancer Research, 2008
- Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell CarcinomaCancer Research, 2005